We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

JEOL

JEOL is a leading global supplier of electron microscopes, ion beam instruments, mass spectrometers and NMR spectrome... read more Featured Products: More products

Download Mobile App





JEOL Ltd. Introduces BioMajesty Series of Clinical Chemistry Analyzers at MEDICA 2019

By LabMedica International staff writers
Posted on 18 Nov 2019
Print article
Image: BioMajesty JCA-ZS050 Clinical Chemistry Analyzer (Photo courtesy of JEOL Ltd.)
Image: BioMajesty JCA-ZS050 Clinical Chemistry Analyzer (Photo courtesy of JEOL Ltd.)
JEOL Ltd. (Tokyo, Japan) introduced its BioMajesty series of clinical chemistry analyzers featuring unique but proven technologies at this year's MEDICA, the world's largest annual medical technology trade fair, which took place from 18-21 November in Düsseldorf, Germany. At the 2019 edition of MEDICA, more than 5,000 exhibitors from 70 countries presented their newest products and ideas. The event also drew more than 120,000 trade visitors from over 170 countries.

JEOL offers the BioMajesty series of clinical chemistry analyzers which use micro volume of samples and reagents to deliver highly-accurate, high-speed processing through the incorporation of a sample dilution tray, which is an outstanding unique feature of all BioMajesty analyzers.

At the 2019 edition of MEDICA, JEOL showcased its BioMajesty series of clinical chemistry analyzers, which include the JCA-ZS050, JCA-BM6070/C and JCA-BM6010/C. The JCA-ZS050 clinical chemistry analyzer is bolstered by the breakthrough technology and unique dilution mechanism of the series. The JCA-ZS050 boasts of extra-micro-volume measurement with minimum 40μL reaction volume. The 1,800 throughput/hour next-generation chemistry analyzer from JEOL brings innovative operation and simple maintenance, while assuring high-precision data empowered by its novel wash mechanism.

The JCA-BM6070/C clinical chemistry analyzer has 2,400 tests/hour throughput, achieving unprecedented ultrafast processing capability in the 2.0-second cycle time. While realizing minimum reaction volume of 60μl by its unique pre-dilution mechanism, it offers high data reliability and excellent cost benefits.

The JCA-BM6010/C is a compact, reliable chemistry system with versatile functions, offering a maximum throughput of 800 tests/hour for photometry and 1,200 tests/hour with ISE. Bolstered by unique micro-volume technology, a strong tradition of BioMajesty series, it streamlines the daily laboratory routine by automatic on-board hemolysis for HbA1c. The JCA-BM6010/C’s0 superior usability with STAT port and Smart Pause/Smart Start features in its optimized space-saving design help deliver more flexibility.

Related Links:
JEOL Ltd.

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.